failure crash no fail rocket cancelled end
Biotech

Roche's oral SERD flunks 1st-line breast cancer phase 3

The trial missed its primary endpoint, tarnishing the record of a drug candidate that hit the mark in adjuvant and second-line settings.
Nick Paul Taylor Mar 9, 2026 6:40am
Prasad

CBER Director Vinay Prasad to depart FDA—again

Mar 6, 2026 5:30pm
How physiology powers biotech innovation

How physiology powers biotech innovation

Brought to you by American Physiological Society
Racecar speeding down a track

Vertex races to FDA after phase 3 kidney disease data impress

Mar 10, 2026 6:20am
breast cancer mammogram

AI could spot heart disease in breast cancer mammograms

Mar 9, 2026 2:25pm
multiple myeloma cells blood flow cancer blood cancer

BMS' CELMoD drug improves myeloma PFS in phase 3

Mar 9, 2026 11:08am
More News

Xenon epilepsy candidate 'blows away' ph. 3 expectations

Mar 9, 2026 10:55am

FDA greenlights backup anti-choking suction device

Mar 9, 2026 10:45am

Tenacia pens $308M Rapport deal for China rights to epilepsy med

Mar 9, 2026 10:30am

AbbVie ties $350M bet to almost 10% weight loss after 12 weeks

Mar 9, 2026 9:50am